Comparison of different routes of vaccination for eliciting antibody responses in the human stomach

Johansson, Eva-Liz; Bergquist, Charlotta; Edebo, Anders; Johansson, Camilla; Svennerholm, Ann‐Mari

doi:10.1016/j.vaccine.2003.09.002

Cited by 64 publications

(43 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intranasal immunization represents a noninvasive, fast, and easy method to induce both humoral and systemic immunity in laboratory animals. In humans, however, nasal immunizations seem to result in antibody responses in the upper airway mucosa but not in intestinal responses (19,20). At present, it is difficult to predict the efficacy of vaccines in protecting against amebiasis in humans, as there is a lack of adequate animal models and E. histolytica has been reported to be able to degrade human IgA in vitro (21).…”

Section: Discussionmentioning

confidence: 99%

Intranasal Immunization with Gal-Inhibitable Lectin plus an Adjuvant of CpG Oligodeoxynucleotides Protects against Entamoeba histolytica Challenge

Ivory

Chadee

2007

Infect Immun

View full text Add to dashboard Cite

The development of an effective amebiasis vaccine could improve child health in the developing world, reducing cases of amebic colitis and liver abscess. An ideal vaccine would be comprised of a well-characterized parasite antigen and an adjuvant, which would have high potency while driving the immune response in a Th1 direction. This study describes a mucosal vaccine composed of the Entamoeba histolytica galactose/N-acetyl-Dgalactosamine-inhibitable lectin (Gal-lectin) and CpG oligodeoxynucleotides (CpG-ODN). The Gal-lectin is a protein involved in parasite virulence and adherence and is known to activate immune cells, while CpG-ODN are known to be potent inducers of type 1-like immune responses. We demonstrated that intranasal administration of the vaccine resulted in strong Gal-lectin-specific Th1 responses and humoral responses. Vaccination induced the production of Gal-lectin-specific T cells and the production of the proinflammatory cytokine gamma interferon. Vaccinated animals had detectable serum anti-Gal-lectin immunoglobulin G (IgG) and stool anti-Gal-lectin IgA capable of blocking parasite adherence to target cells in vitro. One week after immunization, gerbils were challenged intrahepatically with live trophozoites. Vaccinated gerbils had no detectable abscesses after day 5, whereas control gerbils developed larger abscesses. These results show that mucosal vaccination with Gal-lectin and CpG-ODN can induce both systemic and humoral immune responses.Entamoeba histolytica is the enteric protozoan parasite which causes amoebic colitis and liver abscess in humans. This parasite is estimated to infect 8% of the world's population, leading to 50,000 deaths annually (36). Amebic colitis is the most common clinical manifestation of disease as the parasite must first colonize the colon. Intestinal infection by E. histolytica and progression to disease could theoretically be prevented by vaccine intervention targeted to block parasite colonization (26,35). E. histolytica trophozoites are able to colonize the human intestine by adhering to colonic mucins and subsequently to epithelial cells via a cell surface lectin (3). This galactose/Nacetyl-D-galactosamine-inhibitable lectin (Gal-lectin) is a heterodimer containing disulfide-linked light and heavy subunits, the latter of which has high binding specificity for galactose and N-acetyl-D-galactosamine residues (29). The Gal-lectin is a prime vaccine candidate as it is an immunogenic molecule able to induce protection against amebic liver abscess (ALA) in rodent models of the disease (16,27,30). Recently, it has also been reported that there is a correlation between the presence of anti-lectin fecal immunoglobulin A (IgA) antibodies and protection from parasite colonization in humans (12, 13). Mucosal immunity against the parasite seems to be required to prevent infection, and there is substantial evidence suggesting that a colonization-blocking vaccine targeting the parasite Gallectin could prevent trophozoite adherence and thus provide protection against subse...

show abstract

Section: Discussionmentioning

confidence: 99%

Intranasal Immunization with Gal-Inhibitable Lectin plus an Adjuvant of CpG Oligodeoxynucleotides Protects against Entamoeba histolytica Challenge

Ivory

Chadee

2007

Infect Immun

View full text Add to dashboard Cite

show abstract

“…immunization, in the absence of infection, could induce high ASC numbers in rectum but low ASC numbers in duodenum and jejunum, suggesting that the compartmentalization of the immune system may differ among species (14,26). However, i.r.…”

Section: Discussionmentioning

confidence: 99%

Intrarectal Immunization with Rotavirus 2/6 Virus-Like Particles Induces an Antirotavirus Immune Response Localized in the Intestinal Mucosa and Protects against Rotavirus Infection in Mice

Agnello

Hervé

Lavaux

et al. 2006

J Virol

View full text Add to dashboard Cite

Rotavirus (RV) is the main etiological agent of severe gastroenteritis in infants, and vaccination seems the most effective way to control the disease. Recombinant rotavirus-like particles composed of the viral protein 6 (VP6) and VP2 (2/6-VLPs) have been reported to induce protective immunity in mice when administered by the intranasal (i.n.) route. In this study, we show that administration of 2/6-VLPs by the intrarectal (i.r.) route together with either cholera toxin (CT) or a CpG-containing oligodeoxynucleotide as the adjuvant protects adult mice against RV infection. Moreover, when CT is used, RV shedding in animals immunized by the i.r. route is even reduced in comparison with that in animals immunized by the i.n. route. Humoral and cellular immune responses induced by these immunization protocols were analyzed. We found that although i.r. immunization with 2/6-VLPs induces lower RV-specific immunoglobulin G (IgG) and IgA levels in serum, intestinal anti-RV IgA production is higher in mice immunized by the i.r. route. Cellular immune response has been evaluated by measuring cytokine production by spleen and Peyer's patch cells (PPs) after ex vivo restimulation with RV. Mice immunized by the i.n. and i.r. routes display higher gamma interferon production in spleen and PPs, respectively. In conclusion, we demonstrate that i.r. immunization with 2/6-VLPs protects against RV infection in mice and is more efficient than i.n. immunization in inducing an anti-RV immune response in intestinal mucosa.

show abstract

“…También se estudia activamente la mejor vía para inducir respuesta en humanos donde estudios preliminares sugieren que la ruta oral o intrayeyunal es claramente mejor que la rectal o nasal 41 . El desarrollo de vacunas se ha enlentecido por la www.sochinf.cl Vaccinología búsqueda de antígenos protectores.…”

Section: Nuevas Estrategiasunclassified

Vacunas en desarrollo: Helicobacter pylori

2006

Rev. chil. infectol.

View full text Add to dashboard Cite

Vaccines under development: Helicobacter pyloriHelicobacter pylori causes gastrointestinal disease including peptic ulcer and gastric cancer. An H. pylori vaccine is relevant because of the high prevalence of the infection and its associated complications. Extensive use of traditional antimicrobial therapies to eradicate H. pylori is not feasable, specially in developing countries, in part because of their high cost, associated adverse effects, the risk of reinfection, and the emergence of antimicrobial drug resistance. Numerous animal studies have been performed to determine infection outcomes and to explore the feasibility of a vaccine eradication or prevention of infection. These animal models with the possible exception of monkeys, have not been sufficient to address fundamental issues due to controversial results. A human model of H. pylori infection needs to be developed aimed to select an optimum vaccine candidate. The ultimate scientific goal will be to develop field studies using advanced vaccine candidates, but the current state of knowledge does is insufficient and has provided such candidates. These studies need to be designed in order to provide relevant information on immunity and pathogenesis associated to H. pylori.

show abstract

Comparison of different routes of vaccination for eliciting antibody responses in the human stomach

Cited by 64 publications

References 27 publications

Intranasal Immunization with Gal-Inhibitable Lectin plus an Adjuvant of CpG Oligodeoxynucleotides Protects against Entamoeba histolytica Challenge

Intranasal Immunization with Gal-Inhibitable Lectin plus an Adjuvant of CpG Oligodeoxynucleotides Protects against Entamoeba histolytica Challenge

Intrarectal Immunization with Rotavirus 2/6 Virus-Like Particles Induces an Antirotavirus Immune Response Localized in the Intestinal Mucosa and Protects against Rotavirus Infection in Mice

Vacunas en desarrollo: Helicobacter pylori

Contact Info

Product

Resources

About